Tarsus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. The company's product candidate consist TP-03 which is in clinical stage. Tarsus Pharmaceuticals Inc. is based in IRVINE, Calif.
Revenue (Most Recent Fiscal Year) | $17.45M |
Net Income (Most Recent Fiscal Year) | $-135.89M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | -- |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.77 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -348.22% |
Net Margin (Trailing 12 Months) | -- |
Return on Equity (Trailing 12 Months) | -71.12% |
Return on Assets (Trailing 12 Months) | -55.30% |
Current Ratio (Most Recent Fiscal Quarter) | 8.01 |
Quick Ratio (Most Recent Fiscal Quarter) | 7.92 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.11 |
Inventory Turnover (Trailing 12 Months) | 1.81 |
Book Value per Share (Most Recent Fiscal Quarter) | $7.28 |
Earnings per Share (Most Recent Fiscal Quarter) | $-1.01 |
Earnings per Share (Most Recent Fiscal Year) | $-4.62 |
Diluted Earnings per Share (Trailing 12 Months) | $-4.77 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 37.78M |
Free Float | 34.66M |
Market Capitalization | $1.31B |
Average Volume (Last 20 Days) | 0.54M |
Beta (Past 60 Months) | 1.10 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 8.25% |
Percentage Held By Institutions (Latest 13F Reports) | 90.01% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |